Amrubicin is administered intravenously at a dose of 35 mg/m2/day on days 1-3 every 3 weeks

2 trials

Sponsors

Society for the study of previously treated squamous cell lung cancer, St.Marianna University School of Medicine

Conditions

Squamous Cell Lung Cancer

Phase 2

Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Squamous Cell Lung Cancer

Active, not recruitingJPRN-UMIN000004235

Society for the study of previously treated squamous cell lung cancerSquamous Cell Lung Cancer

Start: 2010-10-01Target: 30Updated: 2026-06-29

Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Squamous Cell Lung Cancer

Active, not recruitingJPRN-UMIN000006370

St.Marianna University School of MedicineSquamous Cell Lung Cancer

Start: 2011-09-01Target: 30Updated: 2026-06-29